Your Position:Products>Monoclonals/Polyclonals

Concizumab ELISA Kit

货号:RB9TDY403028
  • Price:Negotiable
  • Click:231

Product Detail

Product Details

ApplicationsELISA
Detection MethodColorimetric
Sensitivity0.156 μg/ml
Detection Range0.31-5 μg/mL
Recovery80-120%
Sample TypePlasma, Serum
Assay TypeQuantitative
Stability and StorageThe stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 20% prior to the expiration date under appropriate storage condition.
Shipping Condition2-8 ℃
Accession NumberP10646
BackgroundConcizumab (mAb 2021) is a high-affinity, humanized, monoclonal IgG4 antibody (mAb) developed by Novo Nordisk A/S. It was directed against the Kunitz-2 domain of human tissue factor (TF) pathway inhibitor (TFPI), designed to target and selectively block the factor X (FX) a (FXa) binding site of TFPI. As a mAb, concizumab has the advantage of being administered subcutaneously, and exhibits good solubility and stability, allowing administration as a liquid formulation via a ready- and easy-to-use portable pen device. Phase 2 trials of concizumab are ongoing for Haemophilia A and B. On 12 October 2017, orphan designation (EU/3/17/1940) was granted by the European Commission to Novo Nordisk A/S, Denmark, for concizumab for the treatment of haemophilia B.
Alternative NamesAnti-TFPI, NN7415, mab2021, 1312299-39-0
NoteFor Research Use Only.